

Douglas R Langbehn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6129714/publications.pdf>

Version: 2024-02-01

129
papers

12,095
citations

39113

52
h-index

31191

106
g-index

133
all docs

133
docs citations

133
times ranked

9685
citing authors

#	ARTICLE	IF	CITATIONS
1	Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease. <i>American Journal of Human Genetics</i> , 2022, 109, 172-179.	2.6	19
2	Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial. <i>Movement Disorders</i> , 2022, , .	2.2	0
3	Cortical Features in Child and Adolescent Carriers of Mutant Huntingtin (mHTT). <i>Journal of Huntington's Disease</i> , 2022, , 1-6.	0.9	1
4	Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children. <i>Movement Disorders</i> , 2022, 37, 1526-1531.	2.2	9
5	Standardizing the CAP Score in Huntington's Disease by Predicting Age-at-Onset. <i>Journal of Huntington's Disease</i> , 2022, 11, 153-171.	0.9	11
6	Behavioral features in child and adolescent huntingtin gene mutation carriers. <i>Brain and Behavior</i> , 2022, 12, .	1.0	3
7	Response to Lee et Al.. <i>American Journal of Human Genetics</i> , 2022, 109, 1341-1342.	2.6	0
8	Age-Related Cognitive Changes as a Function of CAG Repeat in Child and Adolescent Carriers of Mutant Huntingtin. <i>Annals of Neurology</i> , 2021, 89, 1036-1040.	2.8	6
9	Impact of binge drinking during college on resting state functional connectivity. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108935.	1.6	3
10	Composite UHDRS Correlates With Progression of Imaging Biomarkers in Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 1259-1264.	2.2	12
11	Activity or connectivity? A randomized controlled feasibility study evaluating neurofeedback training in Huntington's disease. <i>Brain Communications</i> , 2020, 2, fcaa049.	1.5	10
12	Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials. <i>Movement Disorders</i> , 2020, 35, 2193-2200.	2.2	14
13	Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1051-1060.	1.0	8
14	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2020, 19, 502-512.	4.9	122
15	Behavioral inhibition and reward processing in college binge drinkers with and without marijuana use. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108119.	1.6	6
16	Hypertension Is Associated With an Earlier Age of Onset of Huntington's Disease. <i>Movement Disorders</i> , 2020, 35, 1558-1564.	2.2	8
17	Developmental Trajectory of Height, Weight, and BMI in Children and Adolescents at Risk for Huntington's Disease: Effect of mHTT on Growth. <i>Journal of Huntington's Disease</i> , 2020, 9, 245-251.	0.9	3
18	Reliability and validity of an internalizing symptom scale based on the adolescent and adult Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA). <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 151-160.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Association of CAG Repeats With Long-term Progression in Huntington Disease. <i>JAMA Neurology</i> , 2019, 76, 1375.	4.5	44
20	A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. <i>EBioMedicine</i> , 2019, 48, 568-580.	2.7	104
21	Abnormal brain development in child and adolescent carriers of mutant huntingtin. <i>Neurology</i> , 2019, 93, e1021-e1030.	1.5	72
22	A Pilot Follow-up Study of Older Alcohol-Dependent Adults. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1759-1768.	1.4	3
23	Personality traits and negative consequences associated with binge drinking and marijuana use in college students. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 400-409.	1.1	10
24	Association Between Age and Familial Risk for Alcoholism on Functional Connectivity in Adolescence. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 692-701.	0.3	8
25	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. <i>Lancet Neurology</i> , The, 2019, 18, 165-176.	4.9	82
26	Ensemble Modeling of Neurocognitive Performance Using MRI-Derived Brain Structure Volumes. <i>Lecture Notes in Computer Science</i> , 2019, , 124-132.	1.0	1
27	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. <i>Human Brain Mapping</i> , 2018, 39, 3516-3527.	1.9	19
28	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. <i>Human Brain Mapping</i> , 2018, 39, 1339-1353.	1.9	33
29	Cortical Thickness in Adolescents with a Family History of Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 89-99.	1.4	36
30	CAG...Glutamine codon usage and somatic mosaicism of the HTT cag repeat are modifiers of huntington disease severity. , 2018, , .		0
31	Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	89
32	J12...HD brain-train: enhancing neural plasticity using real-time FMRI neurofeedback training. , 2018, , .		1
33	Validation of a prognostic index for Huntington's disease. <i>Movement Disorders</i> , 2017, 32, 256-263.	2.2	42
34	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	4.9	248
35	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , The, 2017, 16, 601-609.	4.9	272
36	Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 44849.	1.6	45

#	ARTICLE	IF	CITATIONS
37	Operationalizing compensation over time in neurodegenerative disease. <i>Brain</i> , 2017, 140, 1158-1165.	3.7	62
38	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. <i>Human Brain Mapping</i> , 2017, 38, 2819-2829.	1.9	28
39	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. <i>JAMA Neurology</i> , 2017, 74, 1352.	4.5	12
40	Design optimization for clinical trials in early-stage manifest Huntington's disease. <i>Movement Disorders</i> , 2017, 32, 1610-1619.	2.2	11
41	Polyunsaturated fatty acid composition and childhood adversity: Independent correlates of depressive symptom persistence. <i>Psychiatry Research</i> , 2017, 256, 305-311.	1.7	6
42	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. <i>Neurology</i> , 2017, 89, 2495-2502.	1.5	97
43	Test-Retest Reliability of Measures Commonly Used to Measure Striatal Dysfunction across Multiple Testing Sessions: A Longitudinal Study. <i>Frontiers in Psychology</i> , 2017, 8, 2363.	1.1	16
44	D16...White matter microstructure and natural biological variation in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A39.2-A39.	0.9	0
45	D21...Longitudinal compensation in the cognitive network in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A42.1-A42.	0.9	0
46	Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. <i>Human Brain Mapping</i> , 2016, 37, 4615-4628.	1.9	18
47	D20...Operationalising compensation over time in neurodegenerative disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A41.2-A41.	0.9	0
48	A17...HD brain-train: neuroplasticity as a target to improve function in huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A5.3-A5.	0.9	12
49	Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 251-260.	0.9	2
50	Neuropsychiatry and White Matter Microstructure in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 239-249.	0.9	33
51	A SNP in the HTT promoter alters NF- κ B binding and is a bidirectional genetic modifier of Huntington disease. <i>Nature Neuroscience</i> , 2015, 18, 807-816.	7.1	113
52	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 1979-1986.	3.9	209
53	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. <i>Neuropsychologia</i> , 2015, 79, 138-146.	0.7	56
54	Criteria for success in safety and tolerability trials. <i>Lancet Neurology</i> , The, 2015, 14, 24-25.	4.9	1

#	ARTICLE	IF	CITATIONS
55	Results of the citalopram to enhance cognition in Huntington disease trial. <i>Movement Disorders</i> , 2014, 29, 401-405.	2.2	45
56	Scientific rigor and the art of motorcycle maintenance. <i>Nature Biotechnology</i> , 2014, 32, 871-873.	9.4	34
57	Huntington disease: natural history, biomarkers and prospects for therapeutics. <i>Nature Reviews Neurology</i> , 2014, 10, 204-216.	4.9	873
58	Does Interval Between Screening and Baseline Matter in HD Cognitive Clinical Trials?. <i>Journal of Huntington's Disease</i> , 2014, 3, 139-144.	0.9	1
59	Interventional Differences Among Huntington's Disease Patients by Disease Progression in Commercial and Medicaid Populations. <i>Journal of Huntington's Disease</i> , 2014, 3, 355-363.	0.9	9
60	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. <i>Human Brain Mapping</i> , 2013, 34, 519-529.	1.9	113
61	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. <i>Lancet Neurology</i> , The, 2013, 12, 637-649.	4.9	704
62	The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis. <i>Journal of Medical Economics</i> , 2013, 16, 1043-1050.	1.0	32
63	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 517-526.	0.9	29
64	Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington's Disease. <i>Journal of Probability and Statistics</i> , 2012, 2012, 1-19.	0.3	9
65	Patterns of serotonergic antidepressant usage in prodromal Huntington disease. <i>Psychiatry Research</i> , 2012, 196, 309-314.	1.7	22
66	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. <i>Lancet Neurology</i> , The, 2012, 11, 42-53.	4.9	479
67	Neurocognitive signs in prodromal Huntington disease.. <i>Neuropsychology</i> , 2011, 25, 1-14.	1.0	341
68	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 567-579.	0.8	52
69	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. <i>Lancet Neurology</i> , The, 2011, 10, 31-42.	4.9	530
70	Early atrophy of pallidum and accumbens nucleus in Huntington's disease. <i>Journal of Neurology</i> , 2011, 258, 412-420.	1.8	121
71	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. <i>Brain</i> , 2011, 134, 137-142.	3.7	118
72	Suicidal Behavior in Prodromal Huntington Disease. <i>Neurodegenerative Diseases</i> , 2011, 8, 483-490.	0.8	48

#	ARTICLE	IF	CITATIONS
73	Longitudinal change in regional brain volumes in prodromal Huntington disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 405-410.	0.9	220
74	Estimating Premorbid IQ in the Prodromal Phase of a Neurodegenerative Disease. <i>Clinical Neuropsychologist</i> , 2011, 25, 757-777.	1.5	15
75	Self-paced timing detects and tracks change in prodromal Huntington disease.. <i>Neuropsychology</i> , 2010, 24, 435-442.	1.0	79
76	Cerebral cortex structure in prodromal Huntington disease. <i>Neurobiology of Disease</i> , 2010, 40, 544-554.	2.1	142
77	CAG repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 397-408.	1.1	289
78	Challenges assessing clinical endpoints in early Huntington disease. <i>Movement Disorders</i> , 2010, 25, 2595-2603.	2.2	65
79	Hypochondriacal Symptoms Associated With a Less Therapeutic Physician-Patient Relationship. <i>Psychiatry (New York)</i> , 2010, 73, 57-69.	0.3	10
80	Frontal Behaviors Before the Diagnosis of Huntington's Disease and Their Relationship to Markers of Disease Progression: Evidence of Early Lack of Awareness. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 196-207.	0.9	147
81	Striatal and white matter predictors of estimated diagnosis for Huntington disease. <i>Brain Research Bulletin</i> , 2010, 82, 201-207.	1.4	214
82	Earliest functional declines in Huntington disease. <i>Psychiatry Research</i> , 2010, 178, 414-418.	1.7	128
83	Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. <i>NeuroImage</i> , 2010, 49, 2340-2351.	2.1	84
84	The Iowa Personality Disorder Screen. <i>European Journal of Psychological Assessment</i> , 2010, 26, 11-18.	1.7	18
85	Normative data on and psychometric properties of Verbal and Visual Indexes of the RBANS in older adults. <i>Clinical Neuropsychologist</i> , 2009, 23, 39-50.	1.5	9
86	Acid-Sensing Ion Channel-1a in the Amygdala, a Novel Therapeutic Target in Depression-Related Behavior. <i>Journal of Neuroscience</i> , 2009, 29, 5381-5388.	1.7	146
87	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. <i>Lancet Neurology</i> , The, 2009, 8, 791-801.	4.9	856
88	Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT-HD study. <i>Movement Disorders</i> , 2009, 24, 1763-1772.	2.2	128
89	Diffusion Tensor Imaging in Preclinical Huntington's Disease. <i>Brain Imaging and Behavior</i> , 2009, 3, 77-84.	1.1	41
90	Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 484-487.	0.7	45

#	ARTICLE	IF	CITATIONS
91	Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease. Archives of Neurology, 2008, 65, 1582-9.	4.9	71
92	Obsessive and Compulsive Symptoms in Prediagnosed Huntington's Disease. Journal of Clinical Psychiatry, 2008, 69, 1758-1765.	1.1	61
93	Predictors of diagnosis in Huntington disease. Neurology, 2007, 68, 1710-1717.	1.5	42
94	Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain, 2007, 130, 1732-1744.	3.7	181
95	Abnormal Brain Structure in Children With Isolated Clefts of the Lip or Palate. JAMA Pediatrics, 2007, 161, 753.	3.6	133
96	Practice effects in the prediction of long-term cognitive outcome in three patient samples: A novel prognostic index. Archives of Clinical Neuropsychology, 2007, 22, 15-24.	0.3	146
97	Social function in boys with cleft lip and palate: Relationship to ventral frontal cortex morphology. Behavioural Brain Research, 2007, 181, 224-231.	1.2	47
98	A sibling adoption study of adult attachment: The influence of shared environment on attachment states of mind. Attachment and Human Development, 2007, 9, 375-391.	1.2	32
99	Probability of Obsessive and Compulsive Symptoms in Huntington's Disease. Biological Psychiatry, 2007, 61, 415-418.	0.7	52
100	Psychiatric Symptoms in Huntington's Disease before Diagnosis: The Predict-HD Study. Biological Psychiatry, 2007, 62, 1341-1346.	0.7	363
101	Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia, 2007, 45, 1767-1776.	0.7	122
102	Examining the Repeatable Battery for the Assessment of Neuropsychological Status: Factor Analytic Studies in an Elderly Sample. American Journal of Geriatric Psychiatry, 2006, 14, 976-979.	0.6	33
103	Distinguishing between Hypochondriasis and Somatization Disorder: A Review of the Existing Literature. Psychotherapy and Psychosomatics, 2006, 75, 270-281.	4.0	46
104	Incidence of Delirium and Associated Mortality in Hematopoietic Stem Cell Transplantation Patients. Biology of Blood and Marrow Transplantation, 2006, 12, 928-935.	2.0	34
105	Association of a D2S2944 allele with depression specifically among those with substance abuse or antisocial personality. Drug and Alcohol Dependence, 2006, 83, 33-41.	1.6	22
106	Preparing for Preventive Clinical Trials. Archives of Neurology, 2006, 63, 883.	4.9	292
107	Paths of Genetic and Environmental Influence: The Routes Connecting Personality Disorders with Substance Use Disorders. , 2005, 172, 31-53.		0
108	White Matter Volume and Cognitive Dysfunction in Early Huntington's Disease. Cognitive and Behavioral Neurology, 2005, 18, 102-107.	0.5	99

#	ARTICLE	IF	CITATIONS
109	Prevalence and Correlates of Illness Worry in the General Population. <i>Psychosomatics</i> , 2005, 46, 529-539.	2.5	61
110	Contributions of attachment style and perceived social support to lifetime use of illicit substances. <i>Addictive Behaviors</i> , 2005, 30, 1007-1011.	1.7	66
111	A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. <i>Clinical Genetics</i> , 2004, 65, 267-277.	1.0	738
112	Specific phobia of illness. <i>Journal of Anxiety Disorders</i> , 2004, 18, 531-545.	1.5	38
113	fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease. <i>American Journal of Neuroradiology</i> , 2004, 25, 1715-21.	1.2	183
114	Biology-environment interaction and evocative biology-environment correlation: contributions of harsh discipline and parental psychopathology to problem adolescent behaviors. <i>Behavior Genetics</i> , 2003, 33, 205-220.	1.4	69
115	The association of the D2S2944 124 bp allele with recurrent early onset major depressive disorder in women. <i>American Journal of Medical Genetics Part A</i> , 2003, 121B, 39-43.	2.4	23
116	Genetic and environmental risk factors for the onset of drug use and problems in adoptees. <i>Drug and Alcohol Dependence</i> , 2003, 69, 151-167.	1.6	43
117	Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. <i>Comprehensive Psychiatry</i> , 2003, 44, 88-101.	1.5	166
118	Test of an Interpersonal Model of Hypochondriasis. <i>Psychosomatic Medicine</i> , 2003, 65, 292-300.	1.3	102
119	HYPOCHONDRIASIS AND FEAR OF DEATH. <i>Journal of Nervous and Mental Disease</i> , 2002, 190, 503-509.	0.5	50
120	Childhood Antecedents Of Hypochondriasis. <i>Psychosomatics</i> , 2002, 43, 282-289.	2.5	77
121	The association of a HOPA polymorphism with major depression and phobia. <i>Comprehensive Psychiatry</i> , 2002, 43, 404-410.	1.5	15
122	The adult antisocial syndrome with and without antecedent conduct disorder: Comparisons from an adoption study. <i>Comprehensive Psychiatry</i> , 2001, 42, 272-282.	1.5	40
123	Personality Dysfunction Among Somatizing Patients. <i>Psychosomatics</i> , 2001, 42, 320-329.	2.5	65
124	Relationship Between Service Effectiveness and Satisfaction Among Persons Receiving Medicaid Mental Health Services. <i>Psychiatric Services</i> , 2000, 51, 248-250.	1.1	34
125	The Iowa Personality Disorder Screen: Development and Preliminary Validation of a Brief Screening Interview. <i>Journal of Personality Disorders</i> , 1999, 13, 75-89.	0.8	122
126	Health Attitude Survey. <i>Psychosomatics</i> , 1999, 40, 470-478.	2.5	39

#	ARTICLE	IF	CITATIONS
127	Distinct Contributions of Conduct and Oppositional Defiant Symptoms to Adult Antisocial Behavior. Archives of General Psychiatry, 1998, 55, 821.	13.8	60
128	Discriminant analysis using the unweighted sum of binary variables: a comparison of model selection methods. , 1997, 16, 2679-2700.		8
129	Clinical Correlates of Self-Mutilation Among Psychiatric Inpatients. Annals of Clinical Psychiatry, 1993, 5, 45-51.	0.6	93